Participated in Versa Vascular's oversubscribed $27.3M Series C, which also saw David Hovda appointed CEO.
Versa Vascular is a medical technology company dedicated to transforming the treatment of tricuspid valve disease through innovative, minimally invasive solutions
Versa Vascular is a medical technology company dedicated to transforming the treatment of tricuspid valve disease through innovative, minimally invasive solutions.